AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2025)
AbCellera Biologics' Long-Term Investments history spans 6 years, with the latest figure at $93.3 million for Q3 2025.
- For the quarter ending Q3 2025, Long-Term Investments rose 10.96% year-over-year to $93.3 million, compared with a TTM value of $93.3 million through Sep 2025, up 10.96%, and an annual FY2024 reading of $82.3 million, up 24.81% over the prior year.
- Long-Term Investments for Q3 2025 was $93.3 million at AbCellera Biologics, up from $90.4 million in the prior quarter.
- The five-year high for Long-Term Investments was $93.3 million in Q3 2025, with the low at $32.2 million in Q1 2021.
- Average Long-Term Investments over 5 years is $66.4 million, with a median of $65.9 million recorded in 2023.
- Year-over-year, Long-Term Investments soared 6350.38% in 2021 and then dropped 10.68% in 2023.
- Tracing ABCL's Long-Term Investments over 5 years: stood at $50.3 million in 2021, then skyrocketed by 44.14% to $72.5 million in 2022, then fell by 9.08% to $65.9 million in 2023, then rose by 24.81% to $82.3 million in 2024, then rose by 13.37% to $93.3 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Long-Term Investments are $93.3 million (Q3 2025), $90.4 million (Q2 2025), and $81.6 million (Q1 2025).